CARDAMYST™ (Etripamil) Nasal Spray

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is executing a focused strategy to transform the acute treatment of episodic cardiovascular conditions with self-administered therapies. Its core achievement is the U.S. approval and commercial launch of CARDAMYST™ (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT), validating its platform of rapid-onset nasal calcium channel blockers. The company's strategy leverages this platform to expand into adjacent, larger markets like AFib-RVR while building a commercial footprint in cardiology. With a lean operational model and seasoned leadership, Milestone aims to establish a new standard of care for acute cardiac events outside clinical settings.

Therapeutic Areas